





For reauthorization :

1. Chart notes must document clinically meaningful improvement in symptom severity and daily functioning compared to pre-treatment baseline (e.g., improved MG-ADL or QMG scores).

If all the above requirements are met , the medication will be approved for an additional 12 months .

CareSource considers Ultomiris (ravulizumab -cwz) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off -Label policy.

DATE



19. Alhaidar MK, Abumurad S, Soliven B, Rezaia K. Current Treatment of Myasthenia Gravis. *J Clin Med*. 2022;11(6):1597. Published 2022 Mar 14. doi:10.3390/jcm11061597
20. Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. *J Neurol*. 2023;270(8):3862-3875. doi:10.1007/s00415-023-11699-x

Effective date: 01/01/2024

Revised date: 07/19/2023